Newsgroup: it.economia.borsa
Titolo: VICURON (news)

attenzione battaglione l'ultima volta fece +18%..........prese 2000 pezzi
media 13.37 ;o)...
 Vicuron Pharmaceuticals Granted Priority Review of Dalbavancin NDA by FDA
in Complicated Skin and Soft Tissue Infections
24 February 2005, 02:00am ET
Also Receives Acceptance to File Notification
KING OF PRUSSIA, Penn., Feb. 24 /PRNewswire-FirstCall/ -- Vicuron
Pharmaceuticals Inc. (Nasdaq: MICU; Nuovo Mercato) announced today that the
company has received the acceptance to file notification and been granted
Priority Review status by the U.S. Food and Drug Administration (FDA) for
the New Drug Application (NDA) for its investigational agent dalbavancin, a
novel once-weekly antibiotic for the treatment of complicated skin and soft
tissue infections (cSSTIs) including the most difficult to treat strain of
staphylococcus, methicillin-resistant staphylococcus aureus (MRSA). The FDA
grants Priority designation to products which, if approved, would be a
significant improvement in the treatment of a disease.
"We are very pleased with this regulatory development which we believe
further demonstrates the serious underserved medical need that dalbavancin
has the potential to address," said George F. Horner III, President and CEO
of Vicuron. "We expect to commercialize dalbavancin by the first quarter of
2006 pending FDA approval."
Dalbavancin is a novel second-generation lipoglycopeptide agent that belongs
to the same class as vancomycin. Vancomycin is one of the few treatments
available to hospital patients infected with difficult-to-treat strains of
Staphylococcus bacteria, or Staph known as MRSA (methicillin-resistant
Staphylococcus aureus) and MRSE (methicillin-resistant Staphylococcus
epidermidis). Dalbavancin has been specifically designed as an improved
alternative to vancomycin.
The NDA, which was submitted in December of last year, includes results from
more than 1,850 subjects and three Phase 3 trials that evaluated the safety
and efficacy of dalbavancin in patients with SSTIs caused by Gram-positive
bacteria. The Phase 3 clinical trials each met the primary and secondary
endpoints of non-inferiority when compared to linezolid, cefazolin or
vancomycin, three currently used agents for SSTIs. The most common pathogen
isolated in these studies was S. aureus, with more than 400 patients
infected with MRSA.
In vitro studies have shown that in addition to being potent against
clinically important Gram-positive bacteria, dalbavancin is bactericidal
(i.e., kills bacteria rather than merely inhibiting their growth). The
potency, tissue penetration and half-life of dalbavancin may allow for more
convenient dosing regimens than vancomycin. In preclinical studies,
dalbavancin appears to be one of the most potent antibiotics against MRSA,
including multiply drug-resistant S. aureus and certain other Gram-positive
bacteria.

> attenzione battaglione l'ultima volta fece +18%
non solo, ma proviene da una  bella correzione, quindi iu presupposti per un 
bel salto ci sono tutti, entro anche io

come non detto..........................esco 

??? entri esci ma n'somma ti deci di o no ? qua si deve partire

ok vai  dai fai le valige.
non dimenticare il beauty case  di bart, che ci sono i rossetti di chanel 

daccordo ma tu attento a non dimenticare le piu BELLE...
eheheh le BEGHELLEEEEEE

spegni la luce